

# Financial Results for the First Quarter Ended June 30, 2025

## TAKARA BIO INC.

August 8, 2025

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

## Consolidated Financial Results for the 1<sup>st</sup> Quarter: Net Sales

(¥m)	Net sales	Y/Y
Reagents	6,986	+379 +5.7%
Instruments	173	▲47 ▲21.6%
CDMO	1,178	+160 +15.8%
Regenerative Medicine	790	+326 +70.2%
Gene Analysis / testing & Others	388	▲165 ▲29.9%
Gene Therapy	927	+280 +43.3%
Total	9,266	+772 +9.1%

- **Reagents:** Sales increased mainly in BtoB in the U.S., although the global life science research market continues to be sluggish.
- **Instruments:** Sales decreased due to a decline in sales of PCR related instruments.
- **Regenerative Medicine:** Sales increased in total because of the growth in vector manufacturing and quality testing in spite of the decline in sales of cell processing.
- **Gene Analysis / testing & Others:** Sales was declined due to the decrease in the number of orders for large-scale projects and delays in deadlines although the number of orders received increased from the previous fiscal year.
- **Gene Therapy:** Sales increased due to higher sales of RetroNectin®

## Consolidated Financial Results for the 1<sup>st</sup> Quarter: Sales for Reagents by Region

(¥m)	Net sales	Y/Y
Japan	1,240	+51 +4.3%
U.S.	3,604	+537 +17.5%
Europe	833	+65 +8.5%
China	803	▲281 ▲25.9%
Korea	262	▲29 ▲10.0%
India	241	+36 +17.7%
Total	6,986	+379 +5.7%

**Japan:** Sales of application reagents such as Norovirus Test Kit grew, resulting in higher sales.

**U.S.:** Sales of Research/ Catalog products mainly in academia declined because of the reduction of governmental research grants. But BtoB for large customers are recovering, and it's resulting in up 14.5% compared to the same period last year on a local-currency basis in total.

**Europe:** Overall sales of products recovered due to the resumption of R&D activities. On a local currency basis, it was up 8.7% compared to the same period last year.

**China:** Sales declined due to the impact of a special factor in inventory adjustments resulting from the restructuring of the agency system in FY2025. On a local currency basis, it was down 27.0% compared to the same period last year.

2



## Consolidated Financial Results for the 1<sup>st</sup> Quarter: Operating Profit

(¥m)	FY2026	Y/Y
Net sales	9,266	+772 +9.1%
Gross profit	5,003	+649 +14.9%
SG&A expenses	6,800	+811 +13.6%
Operating profit	▲1,796	▲161 —
R&D expenses	1,787	+80 +4.7%

### Factors behind changes in Operating profit (¥m)

Higher unit sales volume	+349
Difference in sales composition	+241
Effects of foreign exchange rate fluctuations	+59

**Increase in gross profit** +649

Increase in R&D expenses	▲80
Reduction of personnel <sup>†</sup> and other expenses	▲731


**Increase in SG&A expenses** ▲811

3

<sup>†</sup> Excluding R&D personnel expenses



## Build a multipolar global manufacturing system to minimize the impact of U.S.-China trade frictions and tariffs



4

\*Ministry of Economy, Trade and Industry "FY2020 Subsidy for Projects to Promote Domestic Investment for Supply Chain Measures"



## Forward-looking Statements

Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, decline in selling power of the Company's existing and new products, disruptions to production, violations of our intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

For more Information : Public & Investor Relations Department  
E-mail: [bio-ir@takara-bio.co.jp](mailto:bio-ir@takara-bio.co.jp)

5



## Reference Information

- Consolidated Financial Results (1Q)
- Net Sales by Category (1Q)
- Reagents Sales by Region (1Q)
- Performance by Subsidiaries (1Q)
- Exchange Rate (1Q)

## Consolidated Financial Results (1Q)

(¥m)	FY2026 1 <sup>st</sup> quarter	Y/Y	
		Change	Ratio
Net sales	9,266	+772	+9.1%
Cost of sales	4,262	+122	+3.0%
Gross profit	5,003	+649	+14.9%
SG&A expenses	6,800	+811	+13.6%
Operating profit	▲1,796	▲161	-
Ordinary profit	▲1,838	▲339	-
Net income attributable to owners of patent	▲1,511	▲463	-

## Net Sales by Category (1Q)

	(¥m)	FY2026 1 <sup>st</sup> quarter	Y/Y	
			Change	Ratio
Reagents		6,986	+379	+5.7%
Instruments		173	▲47	▲21.6%
CDMO		1,178	+160	+15.8%
Regenerative medicine		790	+326	+70.2%
Gene analysis/testing		271	▲153	▲36.2%
Others		116	▲11	▲9.0%
Gene Therapy		927	+280	+43.3%
Total net sales		9,266	+722	+9.1%

## Reagents Sales by Region (1Q)

	(¥m)	FY2026 1 <sup>st</sup> quarter	Y/Y		
			Change	For exchange	Ratio (Exchange excluded)
Japan		1,240	+51	0	+4.3%
U.S.		3,604	+537	+93	+14.5%
Europe		833	+65	▲1	+8.7%
China		803	▲281	+11	▲27.0%
Korea		262	▲29	▲16	▲4.4%
India		241	+36	▲4	+19.7%
Total		6,986	+379	+82	+4.5%

## Performance by Subsidiaries (1Q)

(¥m)	Net sales	Operating profit
Takara Bio (Non-consolidated)	4,189	▲1,327
Takara Bio Europe (Consolidated)	1,295	16
Takara Biotechnology (Dalian)	655	▲70
Takara Biomedical (Beijing)	1,122	▲31
Takara Korea Biomedical	291	28
DSS Takara India	256	44
Takara Bio USA	4,239	▲549

## Exchange Rate (1Q)

(Unit: Yen)	FY2025 1 <sup>st</sup> quarter	FY2026 1 <sup>st</sup> quarter
	Actual	Actual
US dollar	148.62	152.56
Euro	161.32	160.55
Yuan	20.63	20.94
100 Won	11.17	10.51
Rupee	1.79	1.76
Pound	188.50	192.18